SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors
SpringWorks Therapeutics (Nasdaq: SWTX), a commercial-stage biopharmaceutical company, has appointed Dr. Martin Mackay to its Board of Directors. Dr. Mackay brings over 30 years of pharmaceutical and biotech R&D experience, having held leadership roles at Pfizer, AstraZeneca, and Alexion. He is currently the Executive Chairman of Rallybio, a clinical-stage biotech company focused on rare diseases.
CEO Saqib Islam praised Dr. Mackay's expertise in rare diseases and R&D leadership, stating it will be valuable as SpringWorks advances its pipeline. Dr. Mackay expressed enthusiasm for joining the board, citing SpringWorks' potential to make a significant impact in therapeutic areas with tremendous potential.
SpringWorks Therapeutics (Nasdaq: SWTX), un'azienda biopharmaceutica in fase commerciale, ha nominato Dr. Martin Mackay nel suo Consiglio di Amministrazione. Il Dr. Mackay vanta oltre 30 anni di esperienza nella R&D farmaceutica e biotecnologica, avendo ricoperto ruoli di leadership in Pfizer, AstraZeneca e Alexion. Attualmente è il Presidente Esecutivo di Rallybio, un'azienda biotecnologica in fase clinica focalizzata sulle malattie rare.
Il CEO Saqib Islam ha elogiato l'esperienza del Dr. Mackay nel campo delle malattie rare e nella leadership della R&D, affermando che sarà preziosa mentre SpringWorks avanza nel suo portafoglio di prodotti. Il Dr. Mackay ha espresso entusiasmo per l'entrata nel consiglio, citando il potenziale di SpringWorks di avere un impatto significativo in aree terapeutiche con enormi possibilità.
SpringWorks Therapeutics (Nasdaq: SWTX), una empresa biofarmacéutica en etapa comercial, ha nombrado al Dr. Martin Mackay en su Junta Directiva. El Dr. Mackay aporta más de 30 años de experiencia en I+D farmacéutica y biotecnológica, habiendo ocupado roles de liderazgo en Pfizer, AstraZeneca y Alexion. Actualmente es el Presidente Ejecutivo de Rallybio, una empresa biotecnológica en etapa clínica enfocada en enfermedades raras.
El CEO Saqib Islam elogió la experiencia del Dr. Mackay en enfermedades raras y liderazgo en I+D, afirmando que será valiosa a medida que SpringWorks avance en su cartera. El Dr. Mackay expresó entusiasmo por unirse a la junta, citando el potencial de SpringWorks para tener un impacto significativo en áreas terapéuticas con enorme potencial.
SpringWorks Therapeutics (Nasdaq: SWTX)는 상업 단계의 생명공학 회사로, Dr. Martin Mackay를 이사회에 임명했습니다. Mackay 박사는 화이자, 아스트라제네카, 알렉시온에서 여러 리더십 역할을 하며 30년 이상의 제약 및 생명공학 R&D 경험을 가지고 있습니다. 그는 현재 희귀 질환에 초점을 맞춘 임상 단계의 생명공학 회사인 Rallybio의 회장직을 맡고 있습니다.
CEO Saqib Islam은 희귀 질환 및 R&D 리더십에서의 Mackay 박사의 전문성을 높이 평가하며, SpringWorks가 파이프라인을 발전시키는 데 귀중할 것이라고 언급했습니다. Mackay 박사는 이사회 합류에 대한 열정을 표하며, SpringWorks가 엄청난 잠재력을 가진 치료 분야에서 중요한 영향을 미칠 것으로 기대했습니다.
SpringWorks Therapeutics (Nasdaq: SWTX), une entreprise biopharmaceutique en phase commerciale, a nommé Dr. Martin Mackay à son conseil d'administration. Dr. Mackay apporte plus de 30 ans d'expérience en R&D pharmaceutique et biotechnologique, ayant occupé des postes de direction chez Pfizer, AstraZeneca et Alexion. Il est actuellement Président Exécutif de Rallybio, une entreprise biotechnologique en phase clinique axée sur les maladies rares.
Le PDG Saqib Islam a loué l'expertise du Dr. Mackay en matière de maladies rares et de leadership en R&D, affirmant que cela sera précieux alors que SpringWorks fait progresser son portefeuille. Le Dr. Mackay a exprimé son enthousiasme à rejoindre le conseil, citant le potentiel de SpringWorks pour avoir un impact significatif dans des domaines thérapeutiques avec un énorme potentiel.
SpringWorks Therapeutics (Nasdaq: SWTX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, hat Dr. Martin Mackay in seinen Vorstand berufen. Dr. Mackay bringt über 30 Jahre Erfahrung in der pharmazeutischen und biotechnologischen Forschung & Entwicklung mit und hatte Führungspositionen bei Pfizer, AstraZeneca und Alexion inne. Derzeit ist er der Vorstandsvorsitzende von Rallybio, einem biotechnologischen Unternehmen in der klinischen Phase, das sich auf seltene Krankheiten konzentriert.
CEO Saqib Islam lobte Dr. Mackays Expertise in seltenen Krankheiten und R&D-Leitung und erklärte, dass dies wertvoll sein wird, während SpringWorks sein Portfolio weiterentwickelt. Dr. Mackay äußerte Begeisterung über seinen Beitritt zum Vorstand und verwies auf das Potenzial von SpringWorks, einen erheblichen Einfluss in therapeutischen Bereichen mit enormem Potenzial auszuüben.
- Appointment of highly experienced R&D executive Dr. Martin Mackay to the Board of Directors
- Dr. Mackay brings over 30 years of pharmaceutical and biotech R&D experience
- Addition of expertise in rare diseases and global R&D leadership to support pipeline advancement
- None.
STAMFORD, Conn., July 29, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the appointment of Martin Mackay, Ph.D. to the Company’s Board of Directors. Dr. Mackay is a highly accomplished research and development (R&D) executive with more than 30 years of pharmaceutical and biotech R&D experience, including leadership roles at Pfizer, AstraZeneca and Alexion.
“Martin is a proven industry leader whose experience in developing and delivering novel treatments to patients in need is exceptional,” said Saqib Islam, Chief Executive Officer of SpringWorks. “His expertise in rare diseases and unique perspectives leading multiple Research and Development organizations across the globe will be extremely valuable to SpringWorks as we advance and expand our pipeline and execute on our mission to make a meaningful difference in patients’ lives. I am delighted to welcome Martin to the SpringWorks team.”
“I am very pleased to join the SpringWorks Board and work with a group of talented and visionary leaders who are driven by a joint mission to develop and deliver transformative therapies for patients with devastating diseases,” said Dr. Mackay. “I believe SpringWorks is uniquely positioned to make a significant impact in therapeutic areas with tremendous potential, and it is an honor to bring my experience and knowledge to support the important work that SpringWorks is doing.”
Dr. Mackay is a co-founder and Executive Chairman of Rallybio, a privately held clinical-stage biotechnology company focused on severe rare diseases that was incorporated in January 2018. Previously, Dr. Mackay was Executive Vice President, Head of Research and Development at Alexion from 2013 until 2017. Prior to joining Alexion, Dr. Mackay served as President, Research and Development at AstraZeneca from 2010 to 2013, where he led the R&D functions worldwide, including discovery research, clinical development, regulatory affairs, and key related R&D functions. From 1995 to 2009, he held various positions at Pfizer Inc., including Senior Vice President of Worldwide Development, where he was a member of the Executive Leadership Team and led a global organization tasked with advancing a portfolio of investigational medicines across a range of disease areas, and President, Head of Pfizer Pharmatherapeutics, R&D, where he oversaw all aspects of small molecule discovery and development across multiple therapeutic areas. From 1986 to 1995, Dr. Mackay worked at Ciba-Geigy (now Novartis) in the United Kingdom and Switzerland, and held various positions in academic research prior to that time. Dr. Mackay is currently a member of the Board of Directors of Charles River Laboratories and Novo Nordisk. He received a First-Class Honours Degree in microbiology from Heriot-Watt University and his Ph.D. in molecular genetics from the University of Edinburgh.
About SpringWorks Therapeutics
SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. OGSIVEO® (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment, is the Company’s first FDA-approved therapy. SpringWorks also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. In addition to its wholly owned programs, SpringWorks has also entered into multiple collaborations with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients in need.
For more information, visit www.springworkstx.com and follow @SpringWorksTx on X (formerly Twitter), LinkedIn, and YouTube.
Contacts:
Kim Diamond
Vice President, Communications and Investor Relations
Phone: 203-561-1646
Email: kdiamond@springworkstx.com
Samantha Hilson Sandler
Senior Director, Investor Relations
Phone: 203-461-5501
Email: samantha.sandler@springworkstx.com
FAQ
Who is the new Board member appointed by SpringWorks Therapeutics (SWTX)?
What is Dr. Martin Mackay's background in the pharmaceutical industry?
How might Dr. Mackay's appointment benefit SpringWorks Therapeutics (SWTX)?
What is Dr. Martin Mackay's current role outside of SpringWorks Therapeutics (SWTX)?
